Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 175

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 2
Chunk 175
---
 $108,535 in D&O insurance.

Research
and Development Expenses

We
incurred research and development expenses for the three months ended June 30, 2025 and 2024 of $514,814, and $12,955, respectively.
For the three months ended June 30, 2025, compared to the same period in 2024, this represented an increase of $501,859, or 3,874%,
with the details set forth in the table below:

    Three
    Months Ended June 30, 2025 and 2024

    2025

    2024

    $
    Change

    %
    Change

    Consultant
     
    $
    107,408

    $
    107,357

    $
    51

    0
    %

    Lab Gas

    457

    1,452

    (995
    )

    (69
    )%

    Lab Cell Storage

    15,795

    27,272

    (11,477
    )

    (42
    )%

    Chemistry Manufacturing
    and Controls (“CMC”)

    388,629

    (133,780
    ) 

    522,409

    390
    %

    IP Services

    2,525

    10,654

    (8,129
    )

    76
    %

    Total
     
    $
    514,814

    $
    12,955

    $
    501,859

    3,874
    %

The
Company incurred increased research and development expenses for the three months ended June 30, 2025, as compared to the corresponding
period in 2024 primarily as a result of an increase in CMC fees.

Professional
Fees

We
incurred professional expenses for the three months ended June 30, 2025 and 2024 of $1,605,525 and $541,257, respectively. For
the three months ended June 30, 2025, compared to the same period in 2024, this represented an increase of $1,064,268, or 197%,
as a result of increased legal and accounting fees in 2025 due to the Company’s merger.

Other
Expense

We
incurred other expense for the three months ended June 30, 2025 of